Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027391 · ClinicalTrials.gov registry record · NA
Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)
A NA study, sponsored by FDA Office of Orphan Products Development.
- Completed
- Registry status
- NA
- Development phase
- 160
- Enrollment target
NCT00027391: Completed NA study, sponsored by FDA Office of Orphan Products Development.
NCT00027391 is a NA study that has completed, run by FDA Office of Orphan Products Development. The registered enrollment target is 160 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027391, a NA study, has completed, sponsored by FDA Office of Orphan Products Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
Study Summary
This is a study to determine whether albuterol or oxandrolone, alone or in combination, are able to increase strength and muscle mass in patients with FSHD. It also will determine if albuterol given in "pulsed" fashion will have more effect than when given continuously.
Interventions
- DRUG Albuterol
- DRUG Oxandrolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2001-09 |
| Est. Completion | 2004-08 |
| Phase | NA |
What the finished NCT00027391 record still lists
NCT00027391 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Albuterol is the first listed.
NCT00027391 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00027391 about?
NCT00027391 is a clinical study titled "Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)". This is a study to determine whether albuterol or oxandrolone, alone or in combination, are able to increase strength and muscle mass in patients with FSHD. It also will determine if albuterol given in "pulsed" fashion will have more effect than when given continuously.
What is the current status of trial NCT00027391?
This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2001-09. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00027391?
The interventions under investigation include: Albuterol (DRUG), Oxandrolone (DRUG).
Who is sponsoring clinical trial NCT00027391?
This trial is sponsored by FDA Office of Orphan Products Development, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00027391's enrollment target sits among peer trials
160 628th of 2000 higher than 1,347 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia